

COMPANY ANNOUNCEMENT

Grant of New United Kingdom Patent to determine airway patency

HIGHLIGHTS

- United Kingdom Patent No. GB2440466 granted by Intellectual Property Office
- Patent covering Non Invasive Measurement of Airway Patency
- Monitoring and Diagnosis of Obstructive Sleep Apnea and Airway Obstruction as can occur during surgery and asthma attack

11th May 2009 : The Directors of KarmelSonix Limited (the Company or ASX) Melbourne based subsidiary, PulmoSonix Pty Ltd, are pleased to announce that United Kingdom Patent No. GB2440466 (Method and apparatus for monitoring airways) has been granted by the UK Intellectual Property Office.

This patent, together with other previously granted patents, provide additional scope and protection to PulmoSonix’s range of core technologies utilising active acoustic technology. This technology is contained in PulmoSonix’s AirwayClear™ device which utilizes active acoustics to measure and monitor airway patency for diagnosis and/or treatment of various lung and airway conditions, including Obstructive Sleep Apnea, Asthma and Upper Airway Obstruction.

Importantly, it should be noted that this technology has now also been combined with the KSX core technology for the passive monitoring of asthma patients in the implementation of the ASAM (Acoustic Severe Asthma Monitor) device, currently undergoing clinical trials at the Royal Children’s Hospital in Melbourne. The development of this device has in part been funded by the VISTECH grant scheme (a joint initiative of the Victorian and Israeli Governments).

The patents already granted worldwide, in addition to the significant effort underway in expanding the Company’s intellectual portfolio adds to the expanding pipeline of future product developments for KarmelSonix and places the Company in an increasingly strong position to further develop non-invasive tools for a range of pulmonary disorders.

“Wheeze Rate – A New Paradigm in Asthma Management”

For additional information please contact:

Mr. Peter Marks, Chairman	+61 (0)3 9824 8166	Email: Peter@karmelsonix.com
Prof. Noam Gavriely, CMO	+972 544 661 337	Email: Noam@karmelsonix.com
Dr Henry Pinskiel, Director	+ 61 400 313 732	Email: henry@karmelsonix.com

KarmelSonix Ltd. focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders. Asthma affects 6-16% of the population in developed countries with a cost exceeding \$US15 billion in the US alone.

Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests. The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep. The company is focusing its efforts on the commercialization of its innovative product range with special emphasis on the European and North American markets.

“Wheeze Rate – A New Paradigm in Asthma Management”